Intellia Therapeutics, Inc. NTLA
Set alert
11.70 USD -0.77 -6.17%
As of Nov 2, 1:56 PM ET
11.65 Day range 12.61
7.95 52-week range 18.48
- YTD
- +30.14%
- 1 year
- -7.29%
- Open
- 12.60
- Prev close
- 12.47
- Mkt cap
- 1.64B
- Vol
- 1.62M
- Avg vol
- 4.38M
- EPS
- -3.35
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 11.65
- High
- 12.61
- Forward P/E
- -4.86
- Beta
- 1.80
- Short ratio
- 7.63
- Inst. own
- 100.56%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 12.23
- 200-d avg
- 13.08
- 1y target
- 23.11
MAX chart
Events in this range
- Aug 7, 2025Earnings: -0.99; estimate -1.03; surprise 3.88%
- Nov 6, 2025Earnings: -0.92; estimate -1.02; surprise 9.8%
- Aug 6, 2026Earnings: -0.8; estimate -0.79927; surprise -0.09%
- Aug 7, 2026Rating: Evercore ISI Group · In-Line → Outperform
- Oct 6, 2026Rating: Barclays · — → Underweight
- Nov 5, 2026Earnings: —; estimate -0.79699; surprise —%
Signals (32)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| SMA: Bullish | Aug 1, 2026 | 3 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bearish | Jul 1, 2026 | 4 months ago |
| SMA: Bullish | Jun 1, 2026 | 5 months ago |
| SMA: Bullish | Jan 1, 2026 | 10 months ago |
| SMA: Bearish | Nov 1, 2025 | 1 year ago |
| SMA: Bullish | Jul 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 1, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 1, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bullish | Jul 1, 2023 | 3 years ago |
| SMA: Bearish | Apr 1, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 1, 2022 | 4 years ago |
| SMA: Bearish | Dec 1, 2021 | 4 years ago |
| RSI: Overbought | Nov 1, 2020 | 6 years ago |
| SMA: Bullish | Aug 1, 2020 | 6 years ago |
| SMA: Bearish | Jul 1, 2020 | 6 years ago |
| SMA: Bullish | Jun 1, 2020 | 6 years ago |
| MACD: Buy Signal | Jun 1, 2020 | 6 years ago |
| SMA: Bullish | May 1, 2020 | 6 years ago |
| SMA: Bearish | Dec 1, 2019 | 6 years ago |
| SMA: Bullish | Nov 1, 2019 | 7 years ago |
| SMA: Bearish | Aug 1, 2019 | 7 years ago |
| SMA: Bullish | Jul 1, 2019 | 7 years ago |
| SMA: Bearish | Oct 1, 2018 | 8 years ago |
| SMA: Bullish | May 1, 2018 | 8 years ago |
| SMA: Bearish | Mar 1, 2018 | 8 years ago |
| SMA: Bullish | Jun 1, 2017 | 9 years ago |
Financial health
Altman Z-Score
2.51 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
4 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 2
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 3
- P/E 1
- P/B 2
Valuation
P/E -2.4×
FY 2016 5y median -5.6× FY 2025
P/S 14.4×
FY 2016 5y median 51.5× FY 2025
P/B 1.5×
FY 2016 5y median 2.2× FY 2025
P/FCF -2.7×
FY 2016 5y median -6.6× FY 2025
EV/EBITDA -2.3×
FY 2016 5y median -4.9× FY 2025
EV/Sales 13.5×
FY 2016 5y median 44.0× FY 2025
FCF Yield -36.4%
FY 2016 5y median -15.1% FY 2025
Profitability
Gross Margin 76.5%
FY 2016 5y median 79.2% FY 2025
Operating Margin -651.7%
FY 2016 5y median -879.0% FY 2025
Net Margin -609.9%
FY 2016 5y median -896.8% FY 2025
ROE -61.5%
FY 2016 5y median -45.8% FY 2025
ROIC -57.7%
FY 2016 5y median -42.8% FY 2025
ROA -49.0%
FY 2016 5y median -37.0% FY 2025
Growth (YoY)
Revenue 16.9%
FY 2016 FY 2025
Operating Income 17.5%
FY 2016 FY 2025
EPS (diluted) 27.4%
FY 2016 FY 2025
Free Cash Flow 0.0%
FY 2016 FY 2025
Financial Health
Current Ratio 5.1×
FY 2016 5y median 6.1× FY 2025
Quick Ratio 5.1×
FY 2016 5y median 6.1× FY 2025
Debt / Equity 0.1×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA 0.2×
FY 2016 5y median 0.2× FY 2025
Interest Coverage 0.0×
FY 2016 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31